Avertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business Combination
Summary
“We remain steadfast in our commitment to advancing cardiac care and will continue business as usual, focusing on our core mission of empowering providers with Guardian, the world’s first and only heart attack warning system approved by the FDA. We believe Avertix holds a unique position in the market with its Guardian System and are confident in its potential to make a profound impact on the future of cardiac care.” Both companies express their gratitude to their respective teams and advisors for their dedication throughout the merger process. With a robust portfolio of U.S. patents pertaining to Acute Coronary Syndrome (ACS) events, Avertix is at the forefront of innovation in cardiovascular care and is committed to improving patient outcomes and saving lives through advanced medical technologies. BIOS Acquisition Corporation’s leadership and board differentially consists of recognized industry leaders, including CEOs, CFOs, COOs, CSOs, auditors, investors, bankers and experts covering all functional disciplines needed to maximize the value creation opportunity for a healthcare company. The BIOS Acquisition Corporation team has demonstrated commitment to building valuable assets and can be leveraged as true long-term partners who can help maximize the value creation opportunity for a potential business combination.